ESR1 and breast carcinoma: Another existing genetic test aims at identifying PIK3CA mutations that occur in over 1/3 of breast cancers, most often showing an ER-positive/HER2-negative molecular phenotype and which might indicate a poor response to trastuzumab [23,24].